Bannerbild German Brest Group - Studien

DESTINY Breast05 (GBG 103)


T-DXd vs. T-DM1 in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy
(DESTINY-Breast05; NSABP B-60; GBG-103; SOLTI-2001.NCT04622319 )



A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)

Trial overview was presented at the GBG annual meeting 2021.See the video online or download the slides here:

  • TruDy/Destiny-B05 (807 KB)

    TruDy/Destiny-B05 - Trastuzumab Deruxtecan beim HER2-positiven Mammakarzinom, Prof. Dr. Peter A. Fasching, Universitätsklinikum Erlangen.


Trials is open for recruting.


The following documents are available as download:

Berechtigte und angemeldete Benutzer können hier weitere interne Dokumente abrufen. Haben Sie bereits einen Login? Dann melden Sie sich hier an.


Fax: +496102 / 7480-440

Project Management
Viktoria Tierbach
Dr. Ioannis Gkantiragas

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd